SCHEDULE: RA Capital Discloses 9.9% Stake in Rezolute, Inc.

RA Capital Management and affiliated entities have disclosed a 9.9% beneficial ownership stake in Rezolute, Inc. common stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Rezolute, Inc.
• The filing indicates that RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah each beneficially own 9,180,000 shares of Rezolute, Inc. common stock, representing 9.9% of the class.
• RA Capital Healthcare Fund, L.P. beneficially owns 15,302,186 shares of Rezolute, Inc. common stock, also representing 9.9% of the class, based on the filing's stated percentage.
• The percentage of class is calculated based on 92,727,532 shares of common stock outstanding as of November 4, 2025, as reported in Rezolute, Inc.'s Quarterly Report on Form 10-Q.
• RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner of securities held by the Fund.
• Peter Kolchinsky and Rajeev Shah, as managers of RA Capital, may be deemed beneficial owners of securities beneficially owned by RA Capital.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G and disclaim beneficial ownership of the securities other than for the purpose of determining their obligations under Section 13(d) of the Act.

Sentiment

Score: 5

Explanation: The filing is a standard disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative financial results or forward-looking statements.

Future Outlook

NA

Industry Context

This filing indicates a significant ownership stake by a specialized healthcare investment firm, RA Capital Management, in Rezolute, Inc., a company operating in the biotechnology sector. Such disclosures are common for institutional investors taking positions in publicly traded companies, particularly in sectors like biotech where specialized funds often play a key role in financing and strategic oversight.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may be viewed positively, signaling confidence in the company. It also identifies key holders with substantial voting power.
• Company Management: Awareness of a large institutional holder can influence strategic decisions and engagement with investors.

Key Dates

Keywords

Rezolute Inc, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Fund, Biotechnology, Healthcare Investment